Figure 7
The BLA-PL pathway is necessary for expression of the fear-associated memory, but not for reward-seeking behavior. (a) Optogenetic strategy to inhibit BLA inputs to PL. The BLA was bilaterally transfected with either GFP (n = 6 animals) or the opsin ArchT (n = 6 animals), and optical fibers were chronically implanted just above PL to silence BLA inputs locally. (b) Competition paradigm in which half of the trials were paired with constant yellow light to silence BLA inputs to PL. The trial and laser sequences were pseudorandomized. (c) Freezing during CS-Shock trials. Silencing of BLA inputs to PL significantly impaired freezing responses (repeated measures two-way ANOVA: group, F1,10 = 5.64, P = 0.039; laser, F1,10 = 2.75, P = 0.14; interaction, F1,10 = 5.64, P = 0.039; GFP vs ArchT during laser-ON: t10 = 3.36, **P = 0.0072). (d) Port entries during CS-Suc trials. No significant differences were detected on port entry responses (group, F1,10 = 2.53, P = 0.14; laser, F1,10 = 1.70, P = 0.22; interaction, F1,10 = 2.53, P = 0.14). (e) Freezing during competition trials. Significant group differences were detected for freezing during competition (group, F1,10 = 5.20, P = 0.046; laser, F1,10 = 4.37, P = 0.063; interaction, F1,10 = 5.20, P = 0.046; GFP vs ArchT during laser-ON: t10 = 3.23, **P = 0.0091). (f) Port entries during competition trials. Significant group differences were also detected for port entries during competition (group, F1,10 = 10.5, P = 0.009; laser, F1,10 = 9.73, P = 0.011; interaction, F1,10 = 10.5, P = 0.009; GFP vs ArchT during laser-ON: t10 = 4.58, ***P = 0.001). (g) Chemogenetic strategy to selectively silence BLA cell that terminate in PL (i.e., selective inhibition of the BLA-PL population). Using a Cre-dependent dual-virus method, BLA-PL cells were bilaterally transduced with either mCherry (n = 7 animals) or M4D-Gi (n = 7 animals), which is a Gi-coupled designer receptor that induces neuronal silencing upon activation with the designer drug clozapine-N-oxide (CNO). (h) Experimental design to treat animals with either vehicle (5% DMSO in 0.9% saline, i.p.) or CNO (10 mg/kg, i.p.) ~15-20 min prior to behavioral testing. (i) Freezing behavior during CS-Shock trials. Silencing the BLA-PL population significantly impaired freezing responses (group, F1,12 = 3.41, P = 0.09; drug, F2,24 = 7.96, P = 0.0022; interaction, F2,24 = 6.31, P = 0.006; mCherry vs M4D(Gi) during CNO: t12 = 3.66, **P = 0.0033). (j) Port entry behavior during CS-Suc trials. No significant differences were detected (group, F1,12 = 0.13, P = 0.72; drug, F2,24 = 0.69, P = 0.51; interaction, F2,24 = 0.57, P = 0.58). (k) Freezing behavior during competition trials. Silencing of the BLA-PL population impaired freezing responses (group, F1,12 = 1.45, P = 0.25; drug, F2,24 = 0.09, P = 0.91; interaction, F2,24 = 2.67, P = 0.09; mCherry vs M4D(Gi) during CNO: t12 = 2.56, *P = 0.025). (l) Port entry behavior during competition trials. No significant differences were detected (group, F1,12 = 0.13, P = 0.72; drug, F2,24 = 0.60, P = 0.55; interaction, F2,24 = 0.17, P = 0.84). Error bars represent s.e.m.